Posts by Mourabit Halima

In the high summer of 2025, the highly anticipated European Hematology Association (EHA) Annual Meeting was convened, bringing together top global experts in hematologic oncology to discuss cutting-edge progress and future directions in the field. In the Chronic Lymphocytic Leukemia (CLL) session, Dr. Daisy Diaz, a postdoctoral fellow from MD Anderson Cancer Center in the United States, representing the team of her mentor, Professor Deepa Sampath, delivered an exceptional presentation titled "A Study on Transcriptional Reprogramming and Survival Co-dependencies Following Venetoclax Resistance in Chronic Lymphocytic Leukemia." This research systematically unveiled the complex resistance mechanisms in CLL after the failure of Venetoclax treatment and proposed an innovative solution based on Proteolysis-Targeting Chimera (PROTAC) technology, offering a highly promising new approach for clinically overcoming dual-drug resistance.

Editor's Note: At the 30th Annual Congress of the European Hematology Association (EHA) held in Milan, Italy, global hematology experts gathered to share cutting-edge research and clinical breakthroughs. The prestigious…

Acute myeloid leukemia, subtype M2b (AML-M2b), was first identified in 1959 by Professor Chongli Yang at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), based on clinical features, bone marrow morphology, and cytology. He termed it “subacute granulocytic leukemia.” In 1973, Rowley and colleagues abroad reported the same leukemia subtype through cytogenetic methods. By the late 1990s, the team led by Professor Jianxiang Wang demonstrated that the chromosomal translocation t(8;21) leads to rearrangement of the AML1 and ETO genes, producing the AML1-ETO (RUNX1::RUNX1T1) fusion gene—the molecular hallmark of AML-M2b. This marker has since been widely applied in differential diagnosis and minimal residual disease (MRD) monitoring.

Hematologic malignancies such as leukemia, lymphoma, and multiple myeloma remain among the most challenging cancers to treat due to high relapse rates and treatment resistance. Tumor necrosis factor-related apoptosis-inducing ligand…

Primary vitreoretinal lymphoma (PVRL) is a rare but highly aggressive intraocular malignancy closely associated with primary central nervous system lymphoma (PCNSL). Characterized by vague symptoms and high rates of misdiagnosis,…

ZNF618::NUTM1-rearranged B-cell lymphoblastic leukemia (B-ALL) is recognized as a rare but favorable subtype of pediatric leukemia. However, this new case report published in Blood Science challenges that prognostic certainty, documenting a 3-year-old patient whose disease proved resistant to conventional chemotherapy, multiple CAR-T therapies, and hematopoietic stem cell transplantation. The findings underscore the need to reassess expectations surrounding NUTM1 fusion-positive leukemias and investigate the biological complexity behind treatment failure.